HLS Therapeutics Inc Share Price Toronto S.E.
Stocks
AM
CA05328X1015
Pharmaceuticals
OTC Markets Traded
| Market Cap | 95.74M 83.48M 77.21M 72.36M 135M 9.03B 137M 917M 355M 4.45B 359M 352M 15.44B | P/E 2026 * |
-15.3x | P/E 2027 * | -102x |
|---|---|---|---|---|---|
| Enterprise Value | 95.74M 83.48M 77.21M 72.36M 135M 9.03B 137M 917M 355M 4.45B 359M 352M 15.44B | EV / Sales 2026 * |
1.65x | EV / Sales 2027 * | 1.49x |
| Free-Float |
99.48% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: HLS Therapeutics Inc
| Manager | Title | Age | Since |
|---|---|---|---|
Craig Millian
CEO | Chief Executive Officer | 58 | 30/04/2023 |
John Hanna
DFI | Director of Finance/CFO | 61 | 25/01/2024 |
Jason Gross
CTO | Chief Tech/Sci/R&D Officer | 61 | 31/05/2014 |
| Director | Title | Age | Since |
|---|---|---|---|
Rodney Hill
BRD | Director/Board Member | 58 | 11/03/2018 |
John Welborn
CHM | Chairman | 48 | 21/06/2023 |
Norma Beauchamp
BRD | Director/Board Member | 65 | 31/12/2020 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -0.41% | - | - | 94.93M | |
| -3.74% | -4.64% | +2.98% | +84.79% | 87.88B | |
| -1.99% | +0.28% | +34.08% | +143.04% | 51.94B | |
| -1.78% | +2.60% | -14.81% | +224.71% | 22.71B | |
| -1.24% | -2.03% | -9.60% | -26.78% | 7.96B | |
| +2.31% | -2.71% | -31.28% | -32.89% | 7.35B | |
| -2.73% | -2.50% | -10.78% | -36.88% | 6.52B | |
| -1.38% | -7.65% | +12.10% | +14.76% | 6.21B | |
| +1.32% | -0.59% | -1.98% | +17.35% | 5.15B | |
| +1.47% | +2.11% | -5.48% | -13.58% | 3.56B | |
| Average | -0.78% | -0.83% | -2.75% | +41.61% | 22.14B | |
| Weighted average by Cap. | -2.41% | +0.60% | +6.85% | +97.45% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 58.03M 50.6M 46.79M 43.86M 82.11M 5.47B 82.77M 556M 215M 2.69B 218M 213M 9.36B | 64.31M 56.08M 51.86M 48.6M 91M 6.07B 91.73M 616M 239M 2.99B 241M 236M 10.37B |
| Net income | -6.26M -5.46M -5.05M -4.73M -8.86M -591M -8.94M -59.98M -23.24M -291M -23.51M -23.01M -1.01B | -1.05M -916K -847K -794K -1.49M -99.03M -1.5M -10.05M -3.9M -48.75M -3.94M -3.86M -169M |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
